Study Comparing Etanercept 50 mg Once Weekly to 25 mg Twice Weekly in Patients With Ankylosing Spondylitis
Status:
Completed
Trial end date:
2005-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare efficacy, pharmacokinetics, and safety of
investigational formulations of etanercept administered as 50 mg once weekly with 25 mg twice
weekly and placebo in patients with ankylosing spondylitis (AS).